Hepatocellular carcinoma (HCC) is one of the most common malignancies and is the second leading cause of cancer-related death.
Long non-coding RNA (lncRNA), with a minimum length of 200 nucleotides, is an autonomously transcribed RNA that does not encode a protein. 7 LncRNAs have a unique advantage afforded by their abundance, specificity and spatial conformation complexity for regulating gene expression during the development of various diseases, including tumours. [8] [9] [10] Given that lncRNAs can regulate a target gene's transcription by modulating chromatin remodelling, protein scaffolding, promoting RNA decay, ceRNA or enhancer functions, it is likely that they can exhibit different biological functions due to their subcellular localizations. 11, 12 Nuclear-localized lncRNAs regulate gene expression in cis or trans by mediating chromosomal conformation, 13, 14 while cytoplasmic lncRNAs are known to modulate the activity or abundance of interacting miRNAs or mRNAs. 15, 16 Several lncRNAs, including ATB, H19, HOTAIR and HULC, are reported to be related to the tumorigenesis and metastasis of HCC. 10, 17, 18 LncRNAs may be considered facile regulators for controlling the progression of HCC. Our recent study demonstrated that X protein of Hepatitis B Virus (HBx) elevated the potential oncogenic lncRNA UCA1 to promote HCC by repressing p27Kip1. 19 However, it is even more difficult to identify a representative lncRNA that plays an important role in the progression of HCC, such as in metastatic HCC.
TRERNA1 was first identified as an enhancer-like lncRNA. 20 It was also reported that TRERNA1 stimulated tumour invasion in breast cancer. 21 Our previous data showed that lncRNAs were correlated with the lymph node metastasis of GC. 22 Considering that TRERNA1 is involved in the metastasis of multiple tumours, the exploration of the lncRNA TRERNA1 may help to elucidate the mechanism of HCC progression and to evaluate the therapeutic implications for HCC. This will provide new strategies for the diagnosis and treatment of metastatic liver cancer.
| MATERIAL S AND ME THODS

| Cell lines
The immortalized human normal hepatocyte cell line LO2 and the HCC cell lines HepG2, HepG2.215 were purchased from the TCC Cell Bank (Shanghai, China). All cell lines were cultured in RPMI Medium 1640 supplemented with 10% foetal bovine serum, 100 U/ mL penicillin and 100 mg/mL streptomycin (Invitrogen, Carlsbad, CA) in 5% CO 2 at 37°C. 
| HCC tissue specimens
| Plasmid construction and transfection
The sequences of lncRNA TRERNA1 and of the coding gene SNAI1
were cloned into a pcDNA3. The transfected cells were cultured in selection media containing 400 μg/mL G418 (GIBCO, Gaithersburg, MD). Small interfering RNAs (siRNAs) and their respective negative controls were synthesized by GenePharma (Shanghai, China). After transfection with the siRNAs using Lipofectamine 2000 for 48 hours, the RNA or protein of cells was collected for analysis. The sequences of the primers used for plasmid construction and the siRNAs against specific targets in this study are listed in Table S1 .
| RNA isolation and qRT-PCR analysis
Total RNA was isolated from frozen tissues or cultured cells using TRIzol Reagent (Invitrogen, Carlsbad, California, USA), and 1 μg of total RNA was reverse-transcribed using the Reverse Transcription Kit (Takara, Dalian, China). Quantitative real-time PCR (qRT-PCR) was performed on samples in triplicate using SYBR Green (Takara, China) with a StepOne Plus system (Applied Biosystems, Foster City, CA) according to standard quantitative PCR protocol. The expression levels of the tested genes were normalized against the β-actin expression levels as a control by using the 2 -ΔΔCt method.
The primer sequences used for qRT-PCR in this study are listed in Table S2 .
| Wound-healing, cell migration and invasion assays
For the wound-healing assays, cell monolayers were scratched with a clean pipette tip, and cell migration was observed by taking photos under a microscope at 0, 24 and 48 hours after scratching. The cell migration assays were performed using 8.0 mm pore size Transwell inserts (Millipore). The cells (1 × 10 5 cells in 200 μL of serum-free media) were seeded onto the upper surface of the Transwell inserts.
A total of 700 μL of complete medium with serum were added to the bottom wells of the chambers. Invasion was performed with Matrigel (BD Biosciences) following the manufacturer's protocol. Matrigel was polymerized in transwell inserts for 30 minutes at 37°C. For both transwell assays, the cells were incubated for 24 hours (migration assay) or for 48 hours (invasion assay) in 5% CO 2 at 37°C.
The cells at the top of the Transwell were removed using a cotton swab, and the cells that had migrated to the bottom of the wells were stained with a crystal violet/methanol solution. Photographs of three randomly selected fields were taken, and the average number of cells was determined. Both types of assays were repeated in triplicate experiments independently. 
| In vivo xenograft mouse model
| Western blot analysis
Cells were lysed with RIPA lysis buffer and were centrifuged at 18 407 g at 4°C. The protein concentration was quantified using a bicinchoninic acid (BCA) protein assay kit (Beyotime). Identical quantities of protein were separated by 8 ~ 12% sodium dodecyl sulphate-polyacrylamide gel electrophoresis and were transferred onto 0.22 μm PVDF membranes (Sigma). After blocking with 5% non-fat dry milk for 1 hour at room temperature, the membranes were incubated with anti-E-cadherin (Abcam), anti-SNAI1 (R&D) and anti-β-actin (Sigma-Aldrich) as an internal reference. After incubation with the HRP-conjugated secondary antibodies (Sigma), the proteins were detected using a chemiluminescence scanner (Tanon). Table S2 .
| RNA immunoprecipitation (RIP)
RIP
| Chromatin immunoprecipitation (ChIP)
The cells were prepared using the EZ-Magna ChIP™ G Immunoprecipitation Kits (Millipore) according to the manufacturer's instructions. Briefly, the samples were cross-linked with 1% formaldehyde, followed by sonication to make soluble chromatin with DNA fragments between 200 and 700 bp.
Immunoprecipitation was conducted with the following ChIPgrade antibodies: anti-EHMT2 (ab40542), anti-H3K9 me2 (#4658, CST), anti-Pol II (positive control) and normal mouse IgG (negative control). DNA was extracted and was used for RT-PCR or qRT-PCR analyses. The specific primers for CDH1 used are listed in Table S2 .
| Immunoprecipitation assay (IP)
The cell lysates were extracted from cultured HepG2.215 cells at 48 hours. The lysates were separated with centrifugation at 4°C for 15 minutes at 12 000 g. The immunoprecipitation assay was performed according to the standard protocol of the Pierce Classic IP Kit (Thermo). Anti-EHMT2 (Abcam, ab40542) and anti-SNAI1 (R&D)
were used to pull down EHMT2 and SNAI1, respectively. IgG was used as a negative control.
| Statistical analysis
Pearson's chi-square (χ 2 ) test was used to analyse the correlation between the TRERNA1 expression and the clinicopathological characteristics. Pearson's correlation coefficient was calculated to determine the correlation between two variables using Origin 8.0
software. An independent Student's t test (two-tailed) was performed by comparing the results between the two groups; the data are presented as the mean ± SD. A P-value < 0.05 was considered statistically significant (*P < 0.05, **P < 0.01). Error bars represent the mean ± SD, and ns means not significant.
| RE SULTS
| TRERNA1 promotes cell migration and invasion of HCC in vitro
To further understand the association between TRERNA1 and metastatic HCC, we first examined the function of TRERNA1 on cell migration and invasion. After constructing the HepG2-TRERNA1 cell line, the HepG2.215-shTRERNA1 cell line and the corresponding control, the expression levels of TRERNA1 were measured ( Figure   S1A ,B). The exogenous expression of TRERNA1 prompted cell migration and invasion compared with the control cells using both the transwell migration and Matrigel invasion assays. Conversely, the knockdown of TRERNA1 in HepG2.215 cells suppressed cell migration and invasion compared with the control ( Figure 1A ,B).
Similarly, overexpressed TRERNA1 remarkably increased cell mobility in a wound-healing assay ( Figure 1C ). In contrast, knockdown of TRERNA1 significantly reduced the wound healing ability of HCC cells ( Figure 1D ). In other HCC cell lines Huh7 and Hep3B, the ability of cell migration and invasion were also promoted by elevated TRERNA1 level after transiently transfected TRERNA1 or siTRERNA1 in cells, respectively ( Figure S2 ). Taken together, these results demonstrated that TRERNA1 increased the migration and invasion abilities of HCC cells.
| TRERNA1 promotes metastasis of HCC cells in vivo
Subsequently, we evaluated the function of TRERNA1 in promoting HCC metastatic capacity in vivo. We established a liver metastatic played an important role in the promotion of HCC metastasis in vivo.
| TRERNA1 represses CDH1 expression by recruiting EHMT2 to dimethylate H3K9 in the CDH1 promoter region
To explore the mechanism of the TRERNA1 stimulation of HCC metastasis, we evaluated the impact of TRERNA1 on metastasis-related F I G U R E 1 TRERNA1 promotes the cell migration and invasion of HCC in vitro. A, Cell migration assays were performed using transwell assays in HepG2 and HepG2.215 cells. The average number of cells exhibiting migration from three random microscopic fields is presented in the histogram. B, Cell invasion assays were performed using Matrigel-coated transwell membranes. The average number of cells exhibiting invasion from three random microscopic fields is presented in the histogram. C and D, Wound-healing assays in TRERNA1-overexpressing HepG2 cells and in TRERNA1-depleted HepG2.215 cells. The scratch was measured at 0, 24 and 48 h. Data are presented as the mean ± SD; n = 3. *P < 0.05, **P < 0.01
promotes the metastasis of HCC cells in vivo. A and B, Representative livers derived from severe combined immunodeficient (SCID) mice after tail vein injection with HepG2-TRERNA1 and HepG2.215-shTRERNA1 were shown. Haematoxylin and eosin-stained (H&E) images of liver tissues isolated from the mice were shown. Scale bars represent 500 µm (left) and 100 µm (right). Arrows indicate metastasis nodules. C and D, Ectopic TRERNA1 expression promoted the metastasis of HepG2 cells in vivo, and the number of liver metastasis nodules in the mice was determined after 8 weeks (n = 6 per group). E and F, The knockdown of endogenous TRERNA1 by shRNA inhibited the liver metastasis nodules of HepG2.215 cells in nude mice (n = 6 per group). Data are presented as the mean ± SD; **P < 0.01 (Student's t test)
genes, especially the epithelial-mesenchymal transition (EMT)-related genes at the transcript level ( Figure 3A,B) . Figure S3 ). We also noted that the loss of function of E-cadherin often occurs in migratory cells and is related to tumour metastasis. 23 In the present study, we found that elevated TRERNA1 decreased the expression level of CDH1 by Western blotting; conversely, the CDH1 expression level was restored after the knockdown of TRERNA1
( Figure 3C ; Figure S4A ,B). The mechanism by which TRERNA1 induces CDH1 in these cells was further investigated.
Emerging studies have revealed that lncRNAs play divergent roles in epigenetic regulatory networks. 13, 24 Some lncRNAs regulate gene expression by histone methylation via recruiting chromatin regulatory complexes. [25] [26] [27] EHMT2, a major euchromatin methyltransferase responsible for H3K9me2 methylation, can recruit transcription factors during cell biological processes. 28, 29 In an RNA-binding protein immunoprecipitation (RIP) assay, we found a potential physical interaction between TRERNA1 and EHMT2 ( Figure 3D ). Subsequently, RIPqRT-PCR was employed to confirm the binding between TRERNA1
and EHMT2 compared with the binding in IgG controls ( Figure 3E ).
After knocking down EHMT2, the expression level of CDH1 was increased ( Figure 3F ; Figure S4C ). In addition, the reduced enrichment of EHMT2 in the CDH1 promoter region was also observed when TRERNA1 expression was decreased ( Figure 3G,H) . To investigate the potential mechanism by which TRERNA1 inhibits CDH1, an antibody against H3K9me2 was used for ChIP assays. We observed that the inhibition of TRERNA1 reduced the H3K9 dimethylation levels in the CDH1 promoter region ( Figure 3I ). These results suggested that TRERNA1 epigenetically silenced CDH1 by altering its H3K9me2 levels in trans, which depended on EHMT2.
| TRERNA1 recruits EHMT2 for binding with SNAI1 to repress CDH1 expression
In the following immunoprecipitation assays, we found that EHMT2 coprecipitated with SNAI1, a cell migration-related transcriptional factor ( Figure 4A ). SNAI1 is a vital regulator of cell adhesion, migration, invasion and EMT. 30 In our study, the coprecipitation of SNAI1
and EHMT2 was involved in the regulation of TRERNA1 on the expression of E-cadherin encoded by CDH1. Thus, we first examined the effect of SNAI1 on HCC metastasis/CDH1 in our model. SNAI1 mRNA levels also inhibited CDH1 expression ( Figure 4B ). We also found that the reduction in SNAI1 increased the expression of CDH1 at the protein level, while the overexpression of SNAI1 resulted in a reciprocal change ( Figure 4C ; Figure S4D-E) . Surprisingly, TRERNA1 also regulated the protein expression of SNAI1 ( Figure 4D ; Figure S4F ). These data indicate, at least in our model, that TRERNA1 also plays an important role in the regulation of SNAI1, which suggests that the presence of TRERNA1 has an epigenetic role in the regulation of SNAI on CDH1.
To investigate the underlying mechanism whereby TRERNA1 silences CDH1 by binding to EHMT2/SNAI1, the CDH1 expression levels were observed using different treatments with TRERNA1, SNAI1 and EHMT2, taking the EHMT2 coprecipitate with SNAI1
into consideration. As shown in Figure 4E 
| TRERNA1 promotes the ability of SNAI1 to treat HCC metastasis
In our model, SNAI1 is involved in the regulation of CDH1 by TRERNA1; thus, we considered the effect of SNAI1 on the meta- expression in 69 cases showed that TRERNA1 was overexpressed in 53% of HCC tissues ( Figure S5A ). Next, we evaluated the correlation between TRERNA1 mRNA expression levels and clinicopathological characteristics in HCC patients (Table 1) . Kaplan-Meier analysis
showed that high levels of TRERNA1 were significantly associated F I G U R E 6 Overexpressed TRERNA1 levels are correlated with metastasis and are negatively correlated with tumour metastasis repressor gene CDH1 expression in HCC patients. A, The expression levels of TRERNA1 in HCC tissues and in paired, adjacent non-tumour tissues were analysed by qRT-PCR. The horizontal lines in the box plots represent the medians, the boxes represent the interquartile range, and the whiskers represent the 2.5th and 97.5th percentiles. The significant differences were analysed by the Wilcoxon signed-rank test. B, The TRERNA1 expression level in HCC metastasis tissues (n = 37) and in non-metastatic tissues (n = 32). β-actin was used as an internal control. C, The expression level of CDH1 in HCC tissues and in paired adjacent non-tumour tissues by qRT-PCR (n = 69). The horizontal lines in the box plots represent the medians, the boxes represent the interquartile range, and the whiskers represent the 2.5th and 97.5th percentiles. The significant differences were analysed by the Wilcoxon signed-rank test. D, CDH1 expression levels were examined in HCC metastasis tissues (n = 37) and in non-metastatic tissues (n = 32). E, The correlation between the CDH1 mRNA level and the TRERNA1 transcript level was measured by qRT-PCR in metastatic tumour tissues. The 2 -ΔΔCt values (normalized to β-actin) were subjected to Pearson's correlation analysis (P = 4.42178E-4, R 2 = 0.28069). F, The correlation between the CDH1 mRNA level and the TRERNA1 transcript level was measured by qRT-PCR in non-metastatic tumour tissues. The 2 -ΔΔCt values (normalized to β-actin) were subjected to Pearson's correlation analysis (P = 0.21022, R 2 = 0.02021). Data are presented as the mean ± SD; n = 3. *P < 0.05, **P < 0.01 with tumour metastasis (P = 0.021), although there were no remarkable differences between the higher TRERNA1 level group and the lower one in the patients' gender, age and HBs antigen (Table 1) .
Moreover, we observed that high TRERNA1 expression levels were positively correlated with metastatic tumours ( Figure 6B ). All these data showed that the aberrant upregulation of TRERNA1 was correlated with metastasis in HCC, which indicates that TRERNA1 may play an important role in the progression and prognosis of HCC.
qRT-PCR was used to investigate the correlation between TRERNA1 and CDH1 expression in HCC clinical cases. Compared with that in the para-carcinoma tissues, the CDH1 level was decreased in the HCC tumour specimens ( Figure 6C ). We also observed that the CDH1 expression level was significantly reduced in metastatic tumour tissues compared with that in non-metastatic tissues ( Figure 6D ).
In addition, Spearman correlation coefficient analysis showed that there was a significant negative correlation between TRERNA1 and CDH1 in metastatic tumour cases ( Figure 6E ) but not in non-metastatic cases ( Figure 6F ). In an in vivo assay, we monitored the Cdh1 expression levels in nude mice after the injection of HepG2-TRERNA1 cells ( Figure S5B) . A tail vein injection of HepG2.215-shTRERNA1 cells resulted in a higher expression of Cdh1 than the negative controls ( Figure S5C ). We also found increased expression level of Snai1 in injected HepG2-TRERNA1 cells group and decreased expression level of Snai1 in injected HepG2.215-shTRERNA1 cells group ( Figure   S5D -E). Taken together, the results showed that elevated TRERNA1 negatively regulated CDH1, which promoted HCC progression.
| D ISCUSS I ON
Metastatic liver cancer is often more resistant to post-surgical therapy than primary cancers. The mortality and recurrence rates of HCC patients are primarily due to the high metastatic potential. 31, 32 It was generally believed that the occurrence of metastasis, The median expression level was used as the cut-off. HCC, hepatocellular carcinoma a For analysis of correlation between the expression levels of long non-coding RNA TRERNA1 and clinical features of HCC, Pearson chi-square tests were used. Results were considered statistically significant at P < 0 0.05.
F I G U R E 7
A schematic diagram of the lncRNA TRERNA1 functions in HCC metastasis. LncRNA TRERNA1, which could be upregulated in HCC, recruits EHMT2 as a scaffold and forms an EHMT2/SNAI1 complex to suppress the expression of CDH1 via the dimethylation of H3K9 in promoting HCC metastasis a complex process, is ascribed to the regulation of the gene expression of multiple genes. 4 Therefore, elucidating the intricate molecular regulatory mechanisms implicated in HCC metastasis is critical for controlling prognosis. 33 Further insight into the aspects of metastasis can be gleaned by considering the roles of coding genes such as E-cadherin and PTEN. 34 In addition, several non-coding molecules, especially lncRNAs, have been examined for their multiple functions during tumorigenesis.
In contrast to other molecules, lncRNAs display diverse regulatory effects according to their complex space conformations. [35] [36] [37] The formation of secondary and tertiary structures allows lncRNA to interact with proteins as well as DNA or RNA. 37 Thus, exploring the regulatory mechanisms of lncRNAs will provide new ideas for the diagnosis and treatment of metastatic liver cancer.
A recent study showed that lncRNAs play a vital role in controlling tumour progression. The lncRNAs ATB, HAND2-AS1 and FTX have been demonstrated to be related to tumour metastasis. 10, 17, 38 However, due to the complexity of the structures and functions of non-coding RNAs, the exploration of lncRNAs in HCC is far from over. In our study, we report for the first time that the overexpression of TRERNA1 was significantly associated with tumour clinicopathological metastasis characteristics in HCC. In in vitro and in vivo assays, we found that TRERNA1 promoted HCC cell metastasis. Overall, these results convincingly indicated that TRERNA1 plays an important oncogenic role in promoting HCC metastasis.
We detected several markers associated with metastasis and determined whether they were affected by TRERNA1. In particular, and CDH1 in metastatic tumour cases. A comprehensive understanding of the mechanism by which TRERNA1 regulates the coding genes through multiple regulatory pathways will be helpful for the treatment of metastatic tumours, including HCC.
In summary (Figure 7) , we demonstrated that the elevated lncRNA TRERNA1 levels promoted HCC cell metastasis in vitro and in vivo; the aberrant expression of TRERNA1 relates to metastatic HCC and a poor prognosis for patients. TRERNA1 suppresses CDH1 with epigenetic histone modifications via the recruitment of EHMT2 and/ or the EHMT2/SNAI1 complex. Therefore, targeting the lncRNA TRERNA1 might be a novel therapeutic strategy for metastatic HCC. 
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